2020 Guide to Patient Support Services

Astellas Pharma

Astellas Pharma’s Support Solutions offers several support services to eligible patients who are prescribed Astellas Pharma’s oncology medications, including Xospata (gilteritinib), Xtandi (enzalutamide), and Padcev (enfortumab vedotin-ejfv).

Xospata is indicated for the treatment of adults with relapsed or refractory acute myeloid leukemia and an FLT3 mutation, as detected by an FDA-approved test; Xtandi is indicated for the treatment of castration-resistant prostate cancer and for metastatic castration-sensitive prostate cancer; Padcev is indicated for the treatment of adults with locally advanced or metastatic urothelial cancer after treatment with a PD-1 or PD-L1 inhibitor and a platinum-containing chemotherapy (Table).

ASTELLAS SUPPORT SOLUTIONS

Astellas’ Support Solutions offers drug-specific financial assistance programs for Xospata, Xtandi, and Padcev, including a copay assistance program for Xospata and Padcev and a patient assistance program for Xtandi for commercially insured patients, and a quick start program for patients who experience delays in insurance coverage for Xospata or Xtandi. In addition, the Astellas Patient Assistance Program provides medication at no cost for eligible patients who are uninsured or underinsured who have been prescribed Astellas Pharma medication.

For patients with Medicare coverage, Astellas’ Support Solutions can provide drug-specific information about other resources that may help to cover any out-of-pocket cost of their medication.

Through its Support Solutions, Xospata Support Solutions and Xtandi Support Solutions offer the Xospata Copay Card Program and the Xtandi Patient Savings Program. Eligible patients with private health insurance who are enrolled in the Xospata Copay Card Program and have been prescribed Xospata, or patients enrolled in the Xtandi Patient Savings Program who have been prescribed Xtandi may pay as little as $0 per their respective prescription, for a total of 12 months, and a maximum annual benefit of $25,000. These programs have no income restrictions.

Eligible patients who are enrolled in the Padcev Copay Assistance Program and have been prescribed Padcev may pay as little as $5 per their prescription, for a total of 12 months, and a maximum annual benefit of $25,000. This program has no income restrictions.

ELIGIBILITY

To be eligible for prescription support for Xospata, Xtandi, or Padcev through the Xospata Copay Card Program, the Xtandi Patient Savings Program, or the Padcev Copay Assistance Program, patients must:

  • Have private or commercial insurance coverage that covers the respective medication
  • Not have state- or federal-funded programs that will cover the cost of the medication
  • Have a prescription for the relevant medication for an approved indication.

Astellas Patient Assistance Program

This program is for patients without health insurance—although some Medicare Part D patients may be eligible—and provides Xospata, Padcev, or Xtandi free to patients who meet certain criteria. Patients must meet the following eligibility guidelines:

  • Have been prescribed Xospata, Padcev, or Xtandi for an FDA-approved indication
  • Are uninsured or have insurance that excludes coverage for Xospata, Padcev, or Xtandi
  • Meet the program financial eligibility requirements
  • Have a verifiable shipping address within the United States.

Xtandi/Xospata Quick Start+ Program

A free, 1-time, 14-day supply of Xtandi or of Xospata is offered to eligible patients who have a delay in obtaining approval for coverage of Xtandi or Xospata by their insurance provider. The Xtandi or Xospata Quick Start+ Program is for patients who are beginning to use Xtandi or Xospata. Patients who are eligible for this program must:

  • Have prescription drug insurance
  • Be new to Xtandi or Xospata therapy
  • Have experienced an insurance-­related access delay
  • Have been prescribed Xtandi or Xospata for an FDA-approved indication.

Patients with Medicare Coverage

Medicare typically covers Xtandi capsules under the Medicare Part D prescription drug benefit. However, the patient’s cost-sharing may vary among Medicare plans.

For patients who need financial assistance, Astellas Pharma Support Solutions can:

  • Help to determine what type of cost-sharing the patient has, such as a flat copayment or a percentage-based coinsurance
  • Evaluate the patient’s eligibility for Medicare Low-Income Subsidy (or “extra help”)
  • Provide information about other resources.

APPLICATION & ENROLLMENT

To determine whether a patient qualifies for payment assistance, his or her healthcare provider should fill out the Patient Enrollment Form, for Xtandi or Xospata, and fax it to the number on the form.

The provider can call Astellas Pharma Support Solutions or can access Astellas eService at AstellasPharmaSupportSolutions.com to verify drug-specific benefits and cost-sharing requirements and to obtain more information about assistance options.

The patient’s Social Security number is required to assess eligibility for the Astellas Patient Assistance Program.

On receipt of the Patient Enrollment Form, Xtandi Support Solutions performs the benefits verification, which evaluates the patient’s insurance coverage requirements for each medication, requirements for prior authorization, cost-sharing responsibility (including deductibles, coinsurance or copayment, and out-of-pocket maximums), and a list of specialty pharmacies that participate in the patient’s insurance coverage.

Xtandi Quick Start+ Program

A physician, pharmacy, or a member of Astellas Support Solutions staff can initiate the program after the prescriber completes the Quick Start+ portion of the Xtandi or Xospata Support Solutions Patient Enrollment Form.

TABLE ASTELLAS ONCOLOGY DRUGS

Drugs
Indications
Patient support programs

Drug
Padcev (enfortumab vedotin-ejfv) for injection
Indications
Treatment of adults with locally advanced or metastatic urothelial cancer after treatment with a PD-1 or PD-L1 inhibitor and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting
Patient support programs

Drug
Xospata (gilteritinib)
Indications
Treatment of adults with relapsed or refractory acute myeloid leukemia and an FLT3 mutation, as detected by an FDA-approved test
Patient support programs

Drug
Xtandi (enzalutamide) capsules
Indications
Castration-resistant prostate cancer; metastatic castration-sensitive prostate cancer
Patient support programs

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message?

Help us fix it! Report broken links here.

Report Broken Link

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: